February 28, 2019 7:49am

…To be eaten or discarded

It FEELS to ME that there is WEAKNESS … in the air as traders will be picking through sprouts of short-term upside moves

Pre-open indications:  1 SELL and 3 TRADEs

Quarterly and FY18 results: uniQure NV (QURE), Editas Medicine (EDIT) and Sangamo Therapeutics (SGMO)


I answer one question, in which company should investors put, keep and commit their money!

RMi outlines preludes and aftermaths defining the daily dosage of facts and objectivity!


U.S. stock index futures are getting flushed

Dow futures are DOWN -0.12% (-30 points), S&P futures are DOWN -0.21% (-6 points) and NASDAQ futures are DOWN -0.39% (-28 points)


U.S. stock index futures were lower after the U.S.-North Korean summit in Vietnam ended without an agreement – on sanctions;

European stocks were mostly lower as investors stayed up-to-date of geopolitical news;

Asian stocks were declined as Chinese factory activity declined and South Korean “talks” ended


Data docket: first reading of Q4’s real GDP will be released at around 8:30 a.m. ET. Chicago PMI figures for February and Kansas City Federal Reserve's latest survey are both set to follow later in the session.


Thursday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -0.49% DOWNSIDE

The SPDR S&P Biotech ETF (XBI) is NOT indicating

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.17% DOWNSIDE



A day of gloom or some doom as the roller-coaster slows and skips a link!

It FEELS to ME that there is WEAKNESS … in the air as traders will be picking through sprouts of short-term upside moves.

From Tuesday’s closing bell post, “back and forth go share values while volume picks-up as the Advance/Decline Line (A/DL) stays on the right side of the sector’s direction.”

  • The close was positive with an A/DL of 30/14 and 1 flat;
  • 12 out of the 30 upside had higher (than the 3 month average) volume
  • 6 out of the 14 downside experienced greater volume (than the 3 month average)
  • In 19 sessions in February, there were 9 negative and 8 positive closes, 1 holiday and 1 vacation day

Last night, I also stated yesterday was “a busy day of 3 Q4 results, 2 offerings announced – 1 priced and a clinical initiative that got … SOLD into! What is my favorite analogy … the sector and Icarus flying so high and getting burned by the heights and the proximity to the sun?


Companies in my headlights – It’s your decision; I provide an idea and context:

AxoGen (AXGN) closed up +$0.45 to $18.34after Tuesday’s  -$0.16 to $17.89 after announcing an adjusted net loss for the fourth quarter of 2018 was $3.6 million, or $0.09 per share, compared with adjusted net loss of $1.4 million, or $0.04 per share, in Q4/17 – Maintaining SELL;

Intellia therapeutics (NTLA) closed up +$0.92 to $15.43 after Tuesday’s +$0.15 to $14.51. The Q4 net loss was $19.1 million or -$0.43 per share for Q4/18, compared to $24 million or -$0.61 per share during Q4/17.Cash position ($314 M which included marketable securities) was supported by use of its ATM, collaboration revenue while R&D and G&A decreased – TRADE;

CRISPR Therapeutics (CRSP) closed up +$0.53 to $36.73 following Tuesday’s -$3.24 to $36.20. January started out at $29.87 and February at $31.92 which as seen the share price jive and dive as a trading stock – TRADE;

Editas Medicine (EDIT) closed up +$0.23 to $20.95 after Tuesday’s $20.72 and Monday’s $20.93 following last Friday’s $19.87 and the previous Thursday’s $19.73 – TRADE;


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.